Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia

Clinics

Volumn 61, Issue 6, 2006, Pages 545-550

  Antunes, Alberto Azoubel ^a   Freire, Geraldo De Campos ^a   Aiello Filho, Domingos ^a   Cury, José ^a   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Benign prostatic hyperplasia; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE; AGED; ARTICLE; BIOPSY; BRAZIL; CARCINOMA; COMPARATIVE STUDY; ECHOGRAPHY; EPIDEMIOLOGY; HUMAN; INCIDENTAL FINDING; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATECTOMY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY; BRAZIL; CARCINOMA; EPIDEMIOLOGIC METHODS; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845870207     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322006000600010     Document Type: Article

References (17)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Tchetgen MB, Oesterling JE. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am. 1995;22:333-44.
3. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol. 2001;166:172-6.
4. Kuntz RM, Ahyai S, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol. 2004;172:1012-6.
5. Bostwick DG. The pathology of incidental carcinoma. Cancer Surv. 1995;23:7-18.
6. Merrill RM, Wiggins CL. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol. 2002;7:213-9.
7. Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology. 2003;62:451-5.
8. Argyropoulos A, Doumas K, Farmakis A, Aristas O, Kontogeorgos G, Lykourinas M. Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephrol. 2005;39:289-93.
9. Scheckowitz EM, Resnick MI. Imaging of the prostate. Benign prostatic hyperplasia. Urol Clin North Am. 1995;22:321-32.
10. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. American Joint Committee on Cancer Manual for Staging Cancer 1992; (4th edition) Philadelphia, PA, JB Lippincott.
11. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
12. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology. 1994;44:692-8.
13. Wasson JH, Bubolz TA, Lu-Yao GL, Walker-Corkery E, Hammond CS, Barry MJ. Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol. 2000;164:1212-5.
14. Schalken JA, Bergh A, Bono A, Foster C, Gospadarowicz M, Isaacs WB, et al. Molecular prostate cancer pathology: current issues and achievements. Scand J Urol Nephrol Suppl. 2005;(216):82-93.
15. Mariappan P, Chong WL, Sundram M, Mohamed SR. Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. BJU Int. 2004;94:307-10.
16. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000;163:1144-8.
17. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene. 2003;22:6497-507.